A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia

Site PI: Hannah Brown, MD

The primary medication used to treat schizophrenia has had the same mechanism of action for decades. Boston Medical Center is excited to be a site for a clinical trial testing a schizophrenia medication with a novel mechanism of action.

This is a global industry-sponsored clinical trial that aims to investigate the effectiveness of a new medication to treat schizophrenia, KarXT. We are studying the outcome of adjunctive KarXT versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia. This trial is an outpatient study for patients who are already on an antipsychotic medication, but their current medication is ineffective at controlling psychotic symptoms.

KAR-012 involves 8 study visits over 13 weeks. Study visits consist of clinical interviews, self-report measures, physical examinations, and biological tests. All participants that participate in KAR-012 will have the option to continue and transition to another trial, KAR-013. Both studies involve the same medication. KAR-013 involves 18 study visits over the span of one year. To be eligible for the study, participants must be 18-59 years old. Participants are compensated for their time and participation in both KAR-012 and KAR-013. To learn more about the study, please email Amelia Blanton at amelia.blanton@bmc.org

Study Details | A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | ClinicalTrials.gov